These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1428461)

  • 41. Factors to be considered in the evaluation of bioavailability and bioequivalence of topical formulations.
    Borsadia S; Ghanem AH; Seta Y; Higuchi WI; Flynn GL; Behl CR; Shah VP
    Skin Pharmacol; 1992; 5(3):129-45. PubMed ID: 1445703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioavailability and activity of betamethasone 17-benzoate in gel and cream formulations: comparison with proprietary topical corticosteroid preparations in the vasoconstrictor assay.
    Woodford R; Barry BW
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):338-45. PubMed ID: 4208350
    [No Abstract]   [Full Text] [Related]  

  • 43. Cutaneous Pharmacokinetic Approaches to Compare Bioavailability and/or Bioequivalence for Topical Drug Products.
    Raney SG; Ghosh P; Ramezanli T; Lehman PA; Franz TJ
    Dermatol Clin; 2022 Jul; 40(3):319-332. PubMed ID: 35750415
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.
    Barry BW; Woodford R
    Br J Dermatol; 1974 Sep; 91(3):323-38. PubMed ID: 4611447
    [No Abstract]   [Full Text] [Related]  

  • 45. Influences of the vehicle in the spreading and release of betamethasone.
    Molesini S; Urto F; Cvetkovska AD; Bettoli V; Valacchi G; Pecorelli A; Manfredini S; Vertuani S
    Ther Deliv; 2018 Feb; 9(3):177-184. PubMed ID: 29424289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quantification of skin-colour changes induced by topical corticosteroid preparations using the Minolta Chroma Meter.
    Queille-Roussel C; Poncet M; Schaefer H
    Br J Dermatol; 1991 Mar; 124(3):264-70. PubMed ID: 2018732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relevance of polymeric synthetic membranes in topical formulation assessment and drug diffusion study.
    Ng SF; Rouse JJ; Sanderson FD; Eccleston GM
    Arch Pharm Res; 2012 Mar; 35(4):579-93. PubMed ID: 22553050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.
    Barry BW; Woodford R
    Br J Dermatol; 1976 Oct; 95(4):423-5. PubMed ID: 974028
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical bioavailability of diclofenac from locally-acting, dermatological formulations.
    Cordery SF; Pensado A; Chiu WS; Shehab MZ; Bunge AL; Delgado-Charro MB; Guy RH
    Int J Pharm; 2017 Aug; 529(1-2):55-64. PubMed ID: 28636892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing equivalence of innovator and generic formulations of betamethasone dipropionate cream and ointment.
    Sequira J; Berardi M; Chan TM; Letarte J; Malchow R; Pramanick B; Wolkoff HN
    Clin Ther; 1991; 13(6):687-94. PubMed ID: 1790543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Novel Approach to Assess the Potency of Topical Corticosteroids.
    Zvidzayi M; Rath S; Bon C; Abboo S; Kanfer I
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic analysis of the FDA guidance for industry--'Topical dermatologic corticosteroids: in vivo bioequivalence'.
    Leopold CS
    Eur J Pharm Biopharm; 2003 Jul; 56(1):53-8. PubMed ID: 12837481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of reflectance spectrophotometry in the human corticosteroid skin blanching assay.
    Conner DP; Zamani K; Almirez RG; Millora E; Nix D; Shah VP
    J Clin Pharmacol; 1993 Aug; 33(8):707-11. PubMed ID: 8408730
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Percutaneous absorption of topical corticosteroids.
    Wester RC; Maibach HI
    Curr Probl Dermatol; 1993; 21():45-60. PubMed ID: 8299376
    [No Abstract]   [Full Text] [Related]  

  • 55. Objective determination of the bioavailability of dermocorticoids--influence of the formulation.
    Poelman MC; Leveque JL; Le Gall F
    Br J Dermatol; 1984 Jul; 111 Suppl 27():158-62. PubMed ID: 6743548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A method for the assay of topical corticosteroids.
    Marks R; Pongsehirun D; Saylan T
    Br J Dermatol; 1973 Jan; 88(1):69-74. PubMed ID: 4686544
    [No Abstract]   [Full Text] [Related]  

  • 57. Bioequivalence of topical generic products. Part 1: Where are we now?
    Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
    Eur J Pharm Sci; 2018 Oct; 123():260-267. PubMed ID: 30053463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A double-blind controlled comparison of generic and trade-name topical steroids using the vasoconstriction assay.
    Olsen EA
    Arch Dermatol; 1991 Feb; 127(2):197-201. PubMed ID: 1990984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of phosphatidylcholine on the topical bioavailability of corticosteroids assessed by the human skin blanching assay.
    Jacobs M; Martin GP; Marriott C
    J Pharm Pharmacol; 1988 Dec; 40(12):829-33. PubMed ID: 2907573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective topical delivery systems for corticosteroids: dermatological and histological evaluations.
    Eroğlu İ; Azizoğlu E; Özyazıcı M; Nenni M; Gürer Orhan H; Özbal S; Tekmen I; Ertam İ; Ünal İ; Özer Ö
    Drug Deliv; 2016 Jun; 23(5):1502-13. PubMed ID: 25259424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.